Chae Young Kwang, Chiec Lauren, Mohindra Nisha, Gentzler Ryan, Patel Jyoti, Giles Francis
Developmental Therapeutics Program of the Division of Hematology/Oncology, Northwestern University, Chicago, IL, 60611, USA.
Robert H. Lurie Comprehensive Cancer Center of Northwestern University, Chicago, IL, 60611, USA.
Cancer Immunol Immunother. 2017 Jan;66(1):25-32. doi: 10.1007/s00262-016-1913-7. Epub 2016 Oct 19.
Immune checkpoint inhibitors such as pembrolizumab, ipilimumab, and nivolumab, now FDA-approved for use in treating several types of cancer, have been associated with immune-related adverse effects. Specifically, the antibodies targeting the programmed-cell death-1 immune checkpoint, pembrolizumab and nivolumab, have been rarely reported to induce the development of type 1 diabetes mellitus. Here we describe a case of a patient who developed antibody-positive type 1 diabetes mellitus following treatment with pembrolizumab in combination with systemic chemotherapy for metastatic adenocarcinoma of the lung. We will also provide a brief literature review of other rarely reported cases of type 1 diabetes presenting after treatment with pembrolizumab and nivolumab, as well as discussion regarding potential mechanisms of this adverse effect and its importance as these drugs continue to become even more widespread.
免疫检查点抑制剂，如帕博利珠单抗、伊匹木单抗和纳武利尤单抗，现已获美国食品药品监督管理局批准用于治疗多种类型的癌症，这些药物与免疫相关的不良反应有关。具体而言，靶向程序性细胞死亡蛋白1免疫检查点的抗体，即帕博利珠单抗和纳武利尤单抗，很少被报道可诱发1型糖尿病的发生。在此，我们描述了1例患者，该患者在接受帕博利珠单抗联合全身化疗治疗肺转移性腺癌后发生了抗体阳性的1型糖尿病。我们还将简要回顾其他关于帕博利珠单抗和纳武利尤单抗治疗后出现1型糖尿病的罕见报道病例，并讨论这种不良反应的潜在机制以及随着这些药物的使用日益广泛其重要性。
